Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody

American Journal of Transplantation

Volumn 12, Issue 10, 2012, Pages 2630-2640

  Poirier, N ^a,b,c   Mary, C ^a,b,c   Dilek, N ^a,b,c   Hervouet, J ^a,b   Minault, D ^a,b   Blancho, G ^a,d   Vanhove, B ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Effimune SAS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

CD28; costimulation; CTLA 4; GVHD; immunotoxicity

Indexed keywords

CD3 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FR 104; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CROSS LINKING; CYTOKINE RELEASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HAPLORHINI; HUMAN; HUMAN CELL; IMMUNOTOXICITY; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD28; CTLA-4 ANTIGEN; DRUG EVALUATION, PRECLINICAL; FLOW CYTOMETRY; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED NOD; MICE, SCID;

EID: 84867098490     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04164.x     Document Type: Article

References (67)

1. Wing K, Onishi Y, Prieto-Martin P, et al,. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
2. Kendal AR, Chen Y, Regateiro FS, et al,. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 2011; 208: 2043-2053.
3. Akiyama Y, Shirasugi N, Uchida N, et al,. B7/CTLA4 pathway is essential for generating regulatory cells after intratracheal delivery of alloantigen in mice. Transplantation 2002; 74: 732-738.
4. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH,. CTLA-4 regulates induction of anergy in vivo. Immunity 2001; 14: 145-155.
5. Issazadeh S, Zhang M, Sayegh MH, Khoury SJ,. Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. J Immunol 1999; 162: 761-765.
6. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK,. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6: 411-417.
7. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP,. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206: 1717-1725.
8. Zhang T, Fresnay S, Welty E, et al,. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11: 1599-1609.
9. Markees TG, Phillips NE, Gordon EJ, et al,. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101: 2446-2455.
10. Zheng XX, Markees TG, Hancock WW, et al,. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999; 162: 4983-4990.
11. Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA,. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest 2006; 116: 2252-2261.
12. Ansari MJ, Sayegh MH,. Costimulation couture: a designer approach to regulating autoimmunity. J Clin Invest 2006; 116: 2080-2083.
13. Waterhouse P, Penninger JM, Timms E, et al,. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985-988.
14. Phan GQ, Yang JC, Sherry RM, et al,. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377.
15. Lühder F, Höglund P, Allison JP, Benoist C, Mathis D,. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998; 187: 427-432.
16. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK,. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996; 157: 1333-1336.
17. Alegre ML, Frauwirth KA, Thompson CB,. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220-228.
18. Kremer JM, Westhovens R, Leon M, et al,. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915.
19. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
20. Vincenti F, Dritselis A, Kirkpatrick P,. Belatacept. Nat Rev Drug Discov 2011; 10: 655-656.
21. Poirier N, Blancho G, Vanhove B,. Alternatives to calcineurin inhibition in renal transplantation: Belatacept, the first co-stimulation blocker. Immunotherapy 2010; 2: 625-636.
22. Kirk AD, Tadaki DK, Celniker A, et al,. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001; 72: 377-384.
23. Haanstra KG, Ringers J, Sick EA, et al,. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003; 75: 637-643.
24. Butte MJ, Peña-Cruz V, Kim M-J, Freeman GJ, Sharpe AH,. Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45: 3567-3572.
25. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ,. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
26. Yao S, Zhu Y, Zhu G, et al,. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34: 729-740.
27. Poirier N, Blancho G, Vanhove B,. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24: 2-11.
28. Poirier N, Blancho G, Vanhove B,. CD28-Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models? Am J Transpl 2012; 12: 1682-1690.
29. Chen Y, Shen S, Gorentla BK, Gao J, Zhong X-P,. Murine regulatory T Cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol 2012 15; 188: 1698-1707.
30. Vasu C, Prabhakar BS, Holterman MJ,. Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity. J Immunol 2004; 173: 2866-2876.
31. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA,. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25 +regulatory cells. J Immunol 2006; 176: 3321-3329.
32. Li R, Perez N, Karumuthil-Melethil S, Prabhakar BS, Holterman MJ, Vasu C,. Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol 2007; 179: 5191-5203.
33. Sharma MD, Baban B, Chandler P, et al,. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 2570-2582.
34. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR,. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008; 181: 5396-5404.
35. Fu S, Zhang N, Yopp AC, et al,. TGF-beta induces Foxp3 +T-regulatory cells from CD4 + CD25-precursors. Am J Transplant 2004; 4: 1614-1627.
36. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ,. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204: 1765-1774.
37. Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu X-Z,. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood 2011; 117: 3096-3103.
38. Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK,. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 1704-1710.
39. Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, et al,. FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008; 128: 1969-1976.
40. Yu X-Z, Albert MH, Martin PJ, Anasetti C,. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest 2004; 113: 1624-1630.
41. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C,. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164: 4564-4568.
42. Haspot F, Villemain F, Laflamme G, et al,. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002; 99: 2228-2234.
43. Li J, Semple K, Suh W-K, et al,. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. Biol Blood Marrow Transplant 2011; 17: 962-969.
44. Laskowski IA, Pratschke J, Wilhelm MJ, et al,. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13: 519-527.
45. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A,. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 2002; 73: 1310-1317.
46. Guillonneau C, Séveno C, Dugast A-S, et al,. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179: 8164-8171.
47. Urakami H, Ostanin DV, Hünig T, Grisham MB,. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 2006; 38: 3244-3246.
48. Dengler TJ, Szabo G, Sido B, et al,. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation 1999; 67: 392-398.
49. Haspot F, Séveno C, Dugast A-S, et al,. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005; 5: 2339-2348.
50. Dugast A-S, Haudebourg T, Coulon F, et al,. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898-7906.
51. Poirier N, Azimzadeh AM, Zhang T, et al,. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010; 2: 17ra10.
52. Vanhove B, Laflamme G, Coulon F, et al,. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102: 564-570.
53. Shiao SL, McNiff JM, Masunaga T, Tamura K, Kubo K, Pober JS,. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007; 83: 304-313.
54. Suntharalingam G, Perry MR, Ward S, et al,. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
55. Soto PC, Stein LL, Hurtado-Ziola N, Hedrick SM, Varki A,. Relative over-reactivity of human versus chimpanzee lymphocytes: Implications for the human diseases associated with immune activation. J Immunol 2010; 184: 4185-4195.
56. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A,. Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA 2006; 103: 7765-7770.
57. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Public-assessment-report/human/002098/WC500108357.pdf. Accessed June 1, 2012.
58. Findlay L, Eastwood D, Stebbings R, et al,. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods 2010; 352: 1-12.
59. Stebbings R, Findlay L, Edwards C, et al,. ®Cytokine storm in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007; 179: 3325-3331.
60. Shultz LD, Ishikawa F, Greiner DL,. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-130.
61. Wagar EJ, Cromwell MA, Shultz LD, et al,. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol 2000; 165: 518-527.
62. King M, Pearson T, Shultz LD, et al,. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 2008; 126: 303-314.
63. Eastwood D, Findlay L, Poole S, et al,. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010; 161: 512-526.
64. Tary-Lehmann M, Lehmann PV, Schols D, Roncarolo MG, Saxon A,. Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras. J Exp Med 1994; 180: 1817-1827.
65. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA,. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 1997; 159: 3460-3473.
66. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
67. Available at: http://www.circare.org/foia5/tgn1412investigatorbrochure. pdf. Accessed June 1, 2012.